In yesterday’s Wall Street session, Myomo Inc. (AMEX:MYO) shares traded at $0.74, up 19.37% from the previous session.
4 analysts cover Myomo Inc. (AMEX:MYO), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $1.75, we find $2.00. Given the previous closing price of $0.62, this indicates a potential upside of 222.58 percent. MYO stock price is now 43.12% away from the 50-day moving average and -3.54% away from the 200-day moving average. The market capitalization of the company currently stands at $16.15M.
The stock has received a hold rating from 0 analysts and a buy rating from 4. Brokers who have rated the stock have averaged $3.95 as their price target over the next twelve months.
With the price target enhanced from $5 to $7, ROTH Capital Upgraded its rating from Neutral to Buy for Myomo Inc. (AMEX: MYO).
In other news, GUDONIS PAUL R, Chief Executive Officer bought 307,692 shares of the company’s stock on Jan 17. The stock was bought for $100,000 at an average price of $0.33. Upon completion of the transaction, the Chief Executive Officer now directly owns 483,345 shares in the company, valued at $0.36 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 17, Chief Financial Officer HENRY DAVID A bought 76,923 shares of the business’s stock. A total of $25,000 was incurred on buying the stock at an average price of $0.33. This leaves the insider owning 163,527 shares of the company worth $0.12 million. Insiders disposed of 8,552 shares of company stock worth roughly $6328.48 over the past 1 year. A total of 5.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MYO stock. A new stake in Myomo Inc. shares was purchased by AIGH CAPITAL MANAGEMENT LLC during the first quarter worth $1,480,000. WORTH VENTURE PARTNERS, LLC invested $182,000 in shares of MYO during the first quarter. In the first quarter, CITADEL ADVISORS LLC acquired a new stake in Myomo Inc. valued at approximately $37,000. TWO SIGMA SECURITIES, LLC acquired a new stake in MYO for approximately $25,000. ADVISOR GROUP HOLDINGS, INC. purchased a new stake in MYO valued at around $7,000 in the second quarter. In total, there are 23 active investors with 32.80% ownership of the company’s stock.
On Thursday morning Myomo Inc. (AMEX: MYO) stock kicked off with the opening price of $0.6200. During the past 12 months, Myomo Inc. has had a low of $0.37 and a high of $2.31. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.30, and a quick ratio of 2.90. The fifty day moving average price for MYO is $0.5188 and a two-hundred day moving average price translates $0.7618 for the stock.
The latest earnings results from Myomo Inc. (AMEX: MYO) was released for Mar, 2023. According to the Medical Devices Company, earnings per share came in at -$0.11, beating analysts’ expectations of -$0.13 by 0.02. This compares to -$0.41 EPS in the same period last year. The net profit margin was -69.70% and return on equity was -123.50% for MYO. The company reported revenue of $3.45 million for the quarter, compared to $3.87 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.88 percent. For the current quarter, analysts expect MYO to generate $5.74M in revenue.
Myomo Inc.(MYO) Company Profile
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, China, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals and surgery centers, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
